Stock screener

PMN

Conviction 92HealthcareScan · Mon, Jul 20, 2026
Shooting star
PMN$14.92-1.81%
ResistanceSupportVol 14Insider buy
63 bars
Vol MA14 584.4K
Apr 20May 6May 26Jun 11Jul 1Jul 20
ProMIS Neurosciences Inc.PHARMACEUTICAL PREPARATIONSwww.promisneurosciences.com
Price14.92
Change-1.81%
Gap-2.70%
Rel volume93.50×
Avg volume413.58K
Avg $ vol6.06M
SMA 2012.83
SMA 5011.32
SMA 2009.82
Price vs 50+31.80%
Price vs 200+51.82%
MA stackbullish
50/200 cross
Supertrendup · 11.85
RSI (14)66
MACD hist0.15
MACD cross
Stoch %K / %D70 / 74
ADX (14)36
+DI / −DI31 / 9
RSI divergence
MACD divergence
ATR %+7.83%
ADR %8.25%
52w high24.79
52w low0.2895
From 52w high-39.83%
Above 52w low+5051.99%
New 52w highNo
SqueezeOff
Bollinger width50.01%
%B0.83
Donchian pos74.11%
Donchian high16.58
Donchian low10.15
AVWAP (52w high)14.75
vs AVWAP high+1.09%
AVWAP (52w low)14.03
vs AVWAP low+6.34%
OBV trendDown
Chaikin MF (20)-0.71
Today vs 20d93.50×
Avg vol (14d)584.4K
Avg vol (20d)413.58K
Avg $ vol (20d)6.06M
Market cap133.75M
RS 3m (vs SPY)+22.36%
RS 6m (vs SPY)+78.94%
RS line new highYes
Trend template6/8
Technical rank96.1
1 week+16.52%
1 month+43.69%
3 months+29.36%
6 months+82.92%
1 year+3072.73%
YTD+109.04%
P/E-3.37
P/B2.20
P/S
P/FCF-4.76
EPS-22.61
Div yield
ROE-65.42%
ROA-58.92%
Debt/Eq0.00
Current9.92
EV/EBITDA
Gross margin
Net margin
Rev growth
EPS growth-1529.33%
Price target31.13
Target upside108.72%
Analyst ratingBuy
Institutional68.50%
Ent. value69.94M
Revenue
Net income-8.24M
Gross profit
Free cash flow-28.12M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out8.97M
Employees11
ListedFri, Sep 30, 2005
Free float7.88M
Float %87.9%
Short interest203.93K
Days to cover4.8d
Short volume48.4%
Squeeze score50 / 100
Next earnings
EPS forecast
Last EPS vs est−$1.26
Last surprise
Setup gradeA+
Conviction92 / 100
Pattern quality
Tech rank96.1 / 100
Group rank23 / 100
Status lane
Setup direction
Pattern family
Resistance
Support
Days since event
Candle confirmShooting star
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in PMN

All disclosures →
No recent disclosed trades by Congress in PMN. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in PMN · 10 buys

InsiderSideShares
Mandel-Brehm Josh
Director · Option (right to buy) · 2026-05-20
Grant11K
Kaplan Johanne
Chief Development Officer · Option (right to buy) · 2026-05-20
Grant50K
WYMAN WILLIAM W
Director · Option (right to buy) · 2026-05-20
Grant5.5K
Warma Neil K
Chief Executive Officer · Option (right to buy) · 2026-05-20
Grant160K
Williams Eugene
Director · Option (right to buy) · 2026-05-20
Grant5.5K
Milbury Max A.
Principal Accounting Officer · Option (right to buy) · 2026-05-20
Grant18.17K
Alex Slanix Paul
Director · Option (right to buy) · 2026-05-20
Grant5.5K
Shafmaster Madge K.
Director · Option (right to buy) · 2026-05-20
Grant11K
WYMAN WILLIAM W
Director · Option (right to buy) · 2026-05-20
Grant11K
Williams Eugene
Director · Option (right to buy) · 2026-05-20
Grant11K

SEC filings

EDGAR filings in PMN

EDGAR →

No recent SEC filings on file for PMN.

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.